text:
Fox News [1]
Saturday, October 8, 2011
FUKUSHIMA, Japan — A worker hired to help bring the crippled Fukushima nuclear plant under control died suddenly, the third fatality reported among workers at the stricken plant since the March accident, The Wall Street Journal reported Friday.
Plant operator Tokyo Electric Power Co. (TEPCO) said it believed the death Thursday, like the previous two, had nothing to do with exposure to radiation in the plant. It also said the death did not result from overwork, though the company did not disclose the cause.
TEPCO said a male worker in his 50s became ill during a meeting Wednesday morning, before his shift started. He was taken to a hospital immediately, and died the next morning.
"We can't disclose what was cited as the cause on his death certificate because it would amount to violation of privacy," a TEPCO spokesman said.
Full story here. [1]


text:
Luxury Hotels in Luxury hotels Davao (0 Luxury Hotels Listed in Luxury hotels Davao)
- Home > Luxury hotels > Far East > Philippines > Davao
Luxury hotels Davao
All the hotels we feature promise to provide a luxury experience and we're sure you'll find the right hotel to suit your travel needs. You'll find we've listed the full contact details for each hotel as well as the hotels own website link. Many properties offer better rates if you book with them directly rather than with a tour operator or online travel agent, so hopefully you'll be able to secure the best rate for your chosen luxury hotel in Davao.

subset: commoncrawl


text:
By JOHN BOSCHINI
For the Fort Lauderdale Strikers, a win couldn't have come at a better time.
A victory over league-leading Carolina coupled with a Montreal loss put the Strikers nine points clear of the Impact for the final playoff spot. Despite the loss, Carolina clinched a playoff spot with Montreal's loss.
Atlanta's slim hope of riding its recent string of good results to the playoffs was all but extinguished with a 4-0 thrashing at the hands of FC Tampa Bay. Tampa Bay moves into fourth place, two points clear FC Edmonton.
Edmonton failed to put the Islanders under pressure with a 1-0 loss in Puerto Rico. The 2010 USSF Division 2 champs have a solid lock on second place as Edmonton lost its fifth consecutive game.
The NSC Minnesota Stars are back up to third place following their 3-1 victory over Montreal.
Here is a look back at all the action in the NASL over the weekend:
FC Tampa Bay 4, Atlanta Silverbacks 0
Keith Savage scored a goal in each half for a brace as FC Tampa Bay made quick work of the Silverbacks.
Mike Ambersley was the driving force behind Tampa Bay's attack assisting on both of Savage's goals and scoring one for himself toward the end of the first half. Matt Clare scored in the dying minutes to put an exclamation point on the rout. Tampa Bay goalkeeper Jeff Attinella notched his fifth shutout of the season while the club turned in the biggest margin of victory in its history.
Minnesota Stars 3, Montreal Impact 1
Simone Bracalello scored a double in the final 15 minutes to give Minnesota the win.
Defender Neil Hlavaty gave Minnesota the lead with a penalty kick in the 15th minute, but the lead was short lived when Ian Westlake equalized 12 minutes later. Bracalello scored in the 75th minute to give Minnesota the lead and added an insurance goal in extra time.
Fort Lauderdale Strikers 2, Carolina Railhawks 1
Martin Nunez's dramatic, stoppage-time winner against his former team gave Fort Lauderdale a much-needed victory and handed Carolina its third loss of the season.
Walter Restrepo opened the scoring in the 38th minute to give Fort Lauderdale the halftime lead. Chris Nurse equalized for the Railhawks 18 minutes from time, but Nunez's goal gave Fort Lauderdale the win. Carolina remains 12 points ahead of Puerto Rico at the top of the NASL table.
Puerto Rico Islanders 1, Edmonton 0
It took 90 minutes, but the Puerto Rico Islanders finally broke through for a narrow victory.
Both teams combined for just 10 shots, the last of which saw Aaron Pitchkolan score in the final minute. Pitchkolan ranks third among defenders with his third goal of the season.
What did you think of the weekend's games? Impressed with the Strikers' victory? Can Puerto Rico catch Carolina? Is Montreal in trouble?
Share your thoughts below.


text:
Out & About
159 East Franklin Street, Chapel Hill, NC 27514
(919) 967-5048
Visit Their Website
Not Yet Rated
Sign in to add your rating
Not Yet Rated
Sign in to add your rating
Informal sit-down restaurant & cantina for Mexican food & margaritas by the glass or pitcher.
Bandido's at Chapel Hill
159 1/2 East Franklin Street
Chapel Hill, NC
(919) 967-5048
Lunch Hours
Mon-Fri 11:00 a.m. - 2:30 p.m.
Mon-Thu 5:00 p.m. - 9:30 p.m.
Fri-Sat 5:00 p.m - 10:00 p.m
Closed on Sundays.
You can get delivery from this location through
www.tarheeltakeout.com (919)942-7678
**Chapel Hill Location's hours subject to change according to school year schedule**
Is this your business? Update your free WRAL Out & About business profile by emailing us your logo or a picture of your business now.


text:
The stance has been endorsed by the Awami National Party (ANP) which shares the Muttahida Qaumi Movement's aspirations to muster control over the city's spoils.
The MQM has strongly opposed the idea and has questioned the singling out of the metropolitan city especially when there have been voices raised against delimitation in other parts of the country.
Opponents of the idea of delimitation are also of the view that the exercise would prove futile as there could be no headcount without a fresh census, an exercise barely on the horizon.
The Election Commission of Pakistan (ECP) on the other hand has announced that it would go ahead with the apex court's directives and had stated that it would consider proposals from several political parties before amending the demarcations of constituencies.
Although the aim behind the exercise has been to end political polarisation in the city, apprehensions prevail that it may not lead to the desired outcome.
Would it be better if the delimitation exercise was carried out after the upcoming general elections and with new census numbers. Or is it still better yet to go ahead with the exercise in Karachi for the time, in light of the apex court's observation.


text:
Has anyone ever seen the do it yourself railgun link online?
Make sure to click "next step".
They are powered by the capacitors from camera flashes usually
thats not a rail gun though its a stun gun, a rail gun uses electric pulse to move a metal bar through a barrel, so far none have been made that are practical. But those stun guns are fun, you can also make one out of a battery powered bug zapper, these done actualy stun but hurt like hell.
here is my railgun, it is made from 25 disposible cameras that i got for free from my local photo store.
That is not a rail gun this is a rail gun. http://www.benchrest.com/youngrails/
Rail guns
The rail guns are the unlimited class of the benchrest game.
Both are rail guns. One is a very accurate firearm w/o a stock and one is an electric pulse gun with EXTREMELY high velocity (11,000 fps or so). The UT research center (now called the J.J. Pickle Research Center, crooked former US congressman from Austin) is here in Austin. They have been at the forefront of the electric rail gun technology race. I know some guys that work there and the velocities they get are incredible. A piece of plastic weighing about a half pound going over 10K fps has incredible kinetic energy. The shortcoming is and will be the amount of power needed to drive it that fast. They have a nuclear reactor there so I guess power is not a big issue.
|All times are GMT. The time now is 07:48 AM.
Copyright ©2000 - 2017, Jelsoft Enterprises Ltd.


text:
What is the significance of the quote "if they give you ruled paper, write the other way" at the start of the novel Fahrenheit 451?
- print Print
- list Cite
1 Answer
Bradbury was writing the novel in response to a fear of mass media and mass thought control engendered by the rise of television and its entrance into so many American homes. His feeling was that any sort of mass-marketed or mass-accepted distribution of ideas and thoughts and rules was dangerous. So if it was embodied by someone handing you a sheet of ruled paper suggesting that you ought to write in a certain direction, he thought you might as well challenge it by writing the opposite way.
Much of the action of the novel is also pushing towards this theme of challenging what is accepted and being willing to push back, even if it is in a basic form like using paper differently than is expected.


text:
Bucs hire Browns great Earnest Byner to coach running backs
UPDATE: The Tampa Bay Times has confirmed the hiring of Earnest Byner.
POSTED 12:46 p.m.: The Bucs are putting the finishing touches on their coaching staff, turning their attention to the remaining position-coach hires.
The latest development, according to Fox Sports, is the team's interview with Browns great Earnest Byner for the vacant running backs coach position.
Byner has been running backs coach for the Redskins, Titans and Jaguars, the latter of which just replaced him with Sylvester Croom after Jacksonville's recent coaching changes. Byner, 49, played 14 seasons for three teams, but it best remembered for his seven seasons in Cleveland.
Byner totaled 8,261 career rushing yards, 56 touchdowns and was named to two Pro Bowls.


text: +-------------------------------------------------------------------------+ | TPWD News Release 20101116a | +-------------------------------------------------------------------------+ | This page contains only plain text, no HTML formatting codes. | | It is not designed for display in a browser but for copying | | and editing in whatever software you use to lay out pages. | | To copy the text into an editing program: | | --Display this page in your browser. | | --Select all. | | --Copy. | | --Paste in a document in your editing program. | | If you have any suggestions for improving these pages, send | | an e-mail to email@example.com and mention Plain Text Pages. | +-------------------------------------------------------------------------+ [ Note: This item is more than six years old. Please take the publication date into consideration for any date references. ] [ Media Contact: TPWD News, firstname.lastname@example.com, 512-389-8030 ] [TH] Nov. 16, 2010 Texas Partnership for Children in Nature Calls For "Happier, Healthier, Smarter" Kids Statewide Conference Dec. 3-4 in Austin to Probe Problems, Solutions AUSTIN -- "Go outside and play." How many times did today's parents hear that familiar phrase while growing up? Studies say kids today don't hear it enough, and that it's time for a change. Mobile devices and video games have all but replaced the days of playing "Kick the Can" on neighborhood streets with friends, or just hanging out at a park all day. In fact, kids today spend just four to seven minutes outside each day in unstructured outdoor play (like climbing trees), yet more than seven hours each day in front of an electronic screen. "If we don't address this issue today, then what we're facing in the next generation is that children will have a much shorter life span than their parents," said Dr. Kimberly Avila Edwards, a pediatrician at the Texas Center for the Prevention and Treatment of Childhood Obesity at Dell Children's Medical Center of Central Texas and chair of the Texas Pediatric Society obesity committee. Avila's talking about the link between childhood obesity and sedentary indoor lifestyles. She's part of a growing chorus of expert voices from diverse disciplines, all urging steps to reconnect kids and families with nature and the outdoors. The Texas Partnership for Children in Nature will host a conference to address the problem Dec. 3-4 in Austin. The purpose is to present the partnership's strategic plan to educators, conservationists, health practitioners, policymakers and others who care about the issue and can work to implement the plan in their communities. Conference speakers include Carter Smith, Texas Parks and Wildlife Department executive director; Joe Frost, Ph.D., University of Texas at Austin professor emeritus; Kevin Coyle, National Wildlife Federation vice president of education; Elizabeth Goodenough, Ph.D., creator of the PBS documentary Where Do the Children Play?; and Dr. Eduardo Sanchez, Blue Cross Blue Shield of Texas vice president and chief medical officer and former Texas Department of State Health Services commissioner. "As the trend away from outdoor play and learning deepens, we are witnessing sobering consequences for children's health and well-being," said TPWD's Smith. "Additionally, this youngest generation is missing out on critical experiences that lay the foundation for future stewardship of our natural resources." The good news: experts say the problem is solvable. Unlike complex environmental or economic problems, getting families and children back to nature is relatively straightforward and inexpensive. "We can reverse this trend," Smith said. "We can restore our children's well-being and their relationship with Texas's rich natural and cultural heritage." The partnership's roots trace to fall 2009, when a bi-partisan group of Texas legislators asked TPWD, the Texas Education Agency, Texas Department of State Health Services and Texas Department of Agriculture to form a public-private partnership and develop a strategic plan. Over 80 professionals answered the call, including representatives from state and federal agencies, non-profits, businesses, and health, education, natural resource and community organizations. Their discoveries include some sobering statistics: --Children ages 8-to-18 spend an average of 7.5 hours a day, over 50 hours per week, connected to a television, computer, video games and other electronic media. --A child is six times more likely to play a video game than ride a bike. --Texas is home to three of the five cities with the highest obesity rates in the nation. --In the 2009-2010 Fitnessgram school year report, only a little over 8 percent of 12th grade girls and boys were deemed physically fit. --Today's children may be the first generation at risk of having a shorter lifespan than their parents. Conversely, experts found children who play and learn in nature are: --Healthier. Active nature play improves physical conditioning and has a positive effect on emotional well-being and child development. Outdoor play has been linked to reduced risk of myopia and vitamin D deficiency. --Happier. Nature play increases self esteem and reduces stress. Children learn self-discipline and are more cooperative with others. Children feel more capable, confident and connected to nature. --Smarter. Nature play stimulates creativity and improves problem solving. Schools using environmental themes report improved academic performance. And, children who play in nature are more likely to become tomorrow's conservation leaders. Author Richard Louv coined the term "nature deficit disorder" to describe the situation in his best-selling book "Last Child in the Woods" (Algonquin Books, 2005). While the term isn't a medical diagnosis, it cites evidence of psychological, physical and cognitive costs associated with the lack of outdoor time. Experts have responded with practical solutions for parents and schools. For example, the Texas Pediatric Society has developed a Childhood Obesity Toolkit for health care providers that encourages limiting the time children spend on TV, video games, and computers and promoting physical activity, including a "healthy lifestyle prescription" that recommends an hour of outdoor play every day. The National Wildlife Federation recently released a comprehensive report "Whole Child: Developing Mind, Body and Spirit through Outdoor Play" that details how the benefits of playing outside are essential to not only physical wellness, but also mental health. The report notes family time can be a child's best bet to connect with nature. The Austin conference is sponsored by the U.S. Environmental Protection Agency and the Winkler Family Foundation. Registration costs $50 and includes meals. See the conference website for the complete agenda and list of speakers and topics. --- On the Net: http://www.texaschildreninnature.org -30-


text:
TREANDA - bendamustine hydrochloride injection, powder, lyophilized, for solution
Cephalon, Inc.
1.1 Chronic Lymphocytic Leukemia (CLL)
1.2 Non-Hodgkin's Lymphoma (NHL)
2.1 Dosing Instructions for CLL
2.2 Dosing Instructions for NHL
2.3 General Considerations for Tumor Lysis Syndrome
2.4 Reconstitution/Preparation for Intravenous Administration
2.5 Admixture Stability
5.1 Myelosuppression
5.2 Infections
5.3 Infusion Reactions and Anaphylaxis
5.4 Tumor Lysis Syndrome
5.5 Skin Reactions
5.6 Other Malignancies
5.7 Use in Pregnancy
6.1 Clinical Trials Experience in CLL
6.2 Clinical Trials Experience in NHL
6.3 Post-Marketing Experience
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
8.8 Effect of Gender
12.1 Mechanism of Action
12.3 Pharmacokinetics
12.4 Pharmacokinetics/Pharmacodynamics
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14.1 Chronic Lymphocytic Leukemia (CLL)
14.2 Non-Hodgkin's Lymphoma (NHL)
16.1 Safe Handling and Disposal
16.2 How Supplied
16.3 Storage
TREANDA® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.
TREANDA for Injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Recommended Dosage:
The recommended dose is 100 mg/m2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
Dose Delays, Dose Modifications and Reinitiation of Therapy for CLL:
TREANDA administration should be delayed in the event of Grade 4 hematologic toxicity or clinically significant ≥ Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to ≤ Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 109/L, platelets ≥ 75 x 109/L], TREANDA can be reinitiated at the discretion of the treating physician. In addition, dose reduction may be warranted. [See Warnings and Precautions(5.1)]
Dose modifications for hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 50 mg/m2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m2 on Days 1 and 2 of each cycle.
Dose modifications for non-hematologic toxicity: for clinically significant Grade 3 or greater toxicity, reduce the dose to 50 mg/m2 on Days 1 and 2 of each cycle.
Dose re-escalation in subsequent cycles may be considered at the discretion of the treating physician.
Recommended Dosage:
The recommended dose is 120 mg/m2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.
Dose Delays, Dose Modifications and Reinitiation of Therapy for NHL:
TREANDA administration should be delayed in the event of a Grade 4 hematologic toxicity or clinically significant ≥ Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to ≤ Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 109/L, platelets ≥ 75 x 109/L], TREANDA can be reinitiated at the discretion of the treating physician. In addition, dose reduction may be warranted. [See Warnings and Precautions(5.1)]
Dose modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.
Dose modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.
Consider using allopurinol as prevention for patients at high risk of tumor lysis syndrome for the first few weeks of treatment.
Aseptically withdraw the volume needed for the required dose (based on 5 mg/mL concentration) and immediately transfer to a 500 mL infusion bag of 0.9% Sodium Chloride Injection, USP (normal saline). As an alternative to 0.9% Sodium Chloride Injection, USP (normal saline), a 500 mL infusion bag of 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, may be considered. The resulting final concentration of bendamustine HCl in the infusion bag should be within 0.2 – 0.6 mg/mL. The reconstituted solution must be transferred to the infusion bag within 30 minutes of reconstitution. After transferring, thoroughly mix the contents of the infusion bag. The admixture should be a clear and colorless to slightly yellow solution.
Use Sterile Water for Injection, USP, for reconstitution and then either 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, for dilution, as outlined above. No other diluents have been shown to be compatible.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Any unused solution should be discarded according to institutional procedures for antineoplastics.
TREANDA contains no antimicrobial preservative. The admixture should be prepared as close as possible to the time of patient administration.
Once diluted with either 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, the final admixture is stable for 24 hours when stored refrigerated (2-8°C or 36-47°F) or for 3 hours when stored at room temperature (15-30°C or 59-86°F) and room light. Administration of TREANDA must be completed within this period.
TREANDA for Injection single-use vial containing 100 mg of bendamustine HCl as white to off-white lyophilized powder.
TREANDA is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine or mannitol. [See Warnings and Precautions(5.3)]
Patients treated with TREANDA are likely to experience myelosuppression. In the two NHL studies, 98% of patients had Grade 3-4 myelosuppression (see Table 4). Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).
In the event of treatment-related myelosuppression, monitor leukocytes, platelets, hemoglobin (Hgb), and neutrophils closely. In the clinical trials, blood counts were monitored every week initially. Hematologic nadirs were observed predominantly in the third week of therapy. Hematologic nadirs may require dose delays if recovery to the recommended values have not occurred by the first day of the next scheduled cycle. Prior to the initiation of the next cycle of therapy, the ANC should be ≥ 1 x 109/L and the platelet count should be ≥ 75 x 109/L. [See Dosage and Administration(2.1), (2.2)]
Infection, including pneumonia and sepsis, has been reported in patients in clinical trials and in post-marketing reports. Infection has been associated with hospitalization, septic shock and death. Patients with myelosuppression following treatment with TREANDA are more susceptible to infections. Patients with myelosuppression following TREANDA treatment should be advised to contact a physician if they have symptoms or signs of infection.
Infusion reactions to TREANDA have occurred commonly in clinical trials. Symptoms include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred, particularly in the second and subsequent cycles of therapy. Monitor clinically and discontinue drug for severe reactions. Patients should be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Patients who experienced Grade 3 or worse allergic-type reactions were not typically rechallenged. Measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids should be considered in subsequent cycles in patients who have previously experienced Grade 1 or 2 infusion reactions. Discontinuation should be considered in patients with Grade 3 or 4 infusion reactions.
Tumor lysis syndrome associated with TREANDA treatment has been reported in patients in clinical trials and in post-marketing reports. The onset tends to be within the first treatment cycle of TREANDA and, without intervention, may lead to acute renal failure and death. Preventive measures include maintaining adequate volume status, close monitoring of blood chemistry, particularly potassium and uric acid levels, and the use of allopurinol during the first few weeks of TREANDA therapy in patients at high risk.
A number of skin reactions have been reported in clinical trials and post-marketing safety reports. These events have included rash, toxic skin reactions and bullous exanthema. Some events occurred when TREANDA was given in combination with other anticancer agents, so the precise relationship to TREANDA is uncertain. In a study of TREANDA (90 mg/m2) in combination with rituximab, one case of toxic epidermal necrolysis (TEN) occurred. TEN has been reported for rituximab (see rituximab package insert). The relationship to TREANDA cannot be determined. Where skin reactions occur, they may be progressive and increase in severity with further treatment. If skin reactions are severe or progressive, TREANDA should be withheld or discontinued.
There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma. The association with TREANDA therapy has not been determined.
TREANDA can cause fetal harm when administered to a pregnant woman. Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights. [See Use in Specific Populations(8.1)]
The data described below reflect exposure to TREANDA in 349 patients who participated in an actively-controlled trial (N=153) for the treatment of CLL and two single-arm studies (N=176) for the treatment of indolent B-cell NHL. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The following serious adverse reactions have been associated with TREANDA in clinical trials and are discussed in greater detail in other sections of the label.
The data described below reflect exposure to TREANDA in 153 patients. TREANDA was studied in an active-controlled trial. The population was 45-77 years of age, 63% male, 100% white, and had treatment naïve CLL. All patients started the study at a dose of 100 mg/m2 intravenously over 30 minutes on days 1 and 2 every 28 days.
Adverse reactions were reported according to NCI CTC v.2.0. In the randomized CLL clinical study, non-hematologic adverse reactions (any grade) in the TREANDA group that occurred with a frequency greater than 15% were pyrexia (24%), nausea (20%), and vomiting (16%).
Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.
Worsening hypertension was reported in 4 patients treated with TREANDA in the randomized CLL clinical study and none treated with chlorambucil. Three of these 4 adverse reactions were described as a hypertensive crisis and were managed with oral medications and resolved.
The most frequent adverse reactions leading to study withdrawal for patients receiving TREANDA were hypersensitivity (2%) and pyrexia (1%).
Table 1 contains the treatment emergent adverse reactions, regardless of attribution, that were reported in ≥ 5% of patients in either treatment group in the randomized CLL clinical study.
|Number (%) of patients
|System organ class Preferred term
|All Grades
|Grade 3/4
|All Grades
|Grade 3/4
|Total number of patients with at least 1 adverse reaction
|121 (79)
|52 (34)
|96 (67)
|25 (17)
|Gastrointestinal disorders
|31 (20)
|1 (<1)
|21 (15)
|1 (<1)
|24 (16)
|1 (<1)
|9 (6)
|14 (9)
|2 (1)
|5 (3)
|General disorders and administration site conditions
|36 (24)
|6 (4)
|8 (6)
|2 (1)
|14 (9)
|2 (1)
|8 (6)
|13 (8)
|6 (4)
|9 (6)
|1 (<1)
|Immune system disorders
|7 (5)
|2 (1)
|3 (2)
|Infections and infestations
|10 (7)
|12 (8)
|9 (6)
|3 (2)
|1 (<1)
|1 (<1)
|Herpes simplex
|5 (3)
|7 (5)
|Weight decreased
|11 (7)
|5 (3)
|Metabolism and nutrition disorders
|11 (7)
|3 (2)
|2 (1)
|Respiratory, thoracic and mediastinal disorders
|6 (4)
|1 (<1)
|7 (5)
|1 (<1)
|Skin and subcutaneous tissue disorders
|12 (8)
|4 (3)
|7 (5)
|3 (2)
|8 (5)
|2 (1)
The Grade 3 and 4 hematology laboratory test values by treatment group in the randomized CLL clinical study are described in Table 2. These findings confirm the myelosuppressive effects seen in patients treated with TREANDA. Red blood cell transfusions were administered to 20% of patients receiving TREANDA compared with 6% of patients receiving chlorambucil.
|Laboratory Abnormality
|All Grades
n (%)
|Grade 3/4
n (%)
|All Grades
n (%)
|Grade 3/4
n (%)
|134 (89)
|20 (13)
|115 (82)
|12 (9)
|116 (77)
|16 (11)
|110 (78)
|14 (10)
|92 (61)
|42 (28)
|26 (18)
|4 (3)
|102 (68)
|70 (47)
|27 (19)
|6 (4)
|113 (75)
|65 (43)
|86 (61)
|30 (21)
In the randomized CLL clinical study, 34% of patients had bilirubin elevations, some without associated significant elevations in AST and ALT. Grade 3 or 4 increased bilirubin occurred in 3% of patients. Increases in AST and ALT of Grade 3 or 4 were limited to 1% and 3% of patients, respectively. Patients treated with TREANDA may also have changes in their creatinine levels. If abnormalities are detected, monitoring of these parameters should be continued to ensure that significant deterioration does not occur.
The data described below reflect exposure to TREANDA in 176 patients with indolent B-cell NHL treated in two single-arm studies. The population was 31-84 years of age, 60% male, and 40% female. The race distribution was 89% White, 7% Black, 3% Hispanic, 1% other, and <1% Asian. These patients received TREANDA at a dose of 120 mg/m2 intravenously on Days 1 and 2 for up to 8 21-day cycles.
The adverse reactions occurring in at least 5% of the NHL patients, regardless of severity, are shown in Table 3. The most common non-hematologic adverse reactions (≥30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%). The most common non-hematologic Grade 3 or 4 adverse reactions (≥5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.
|System organ class
|Number (%) of patients*
|Preferred term
|All Grades
|Grade 3/4
|Total number of patients with at least 1 adverse reaction
|176 (100)
|94 (53)
|Cardiac Disorders
|13 (7)
|Gastrointestinal disorders
|132 (75)
|7 (4)
|71 (40)
|5 (3)
|65 (37)
|6 (3)
|51 (29)
|1 (<1)
|27 (15)
|1 (<1)
|Abdominal pain
|22 (13)
|2 (1)
|20 (11)
|Gastroesophageal reflux disease
|18 (10)
|Dry mouth
|15 (9)
|1 (<1)
|Abdominal pain upper
|8 (5)
|Abdominal distension
|8 (5)
|General disorders and administration site conditions
|101 (57)
|19 (11)
|59 (34)
|3 (2)
|24 (14)
|Edema peripheral
|23 (13)
|1 (<1)
|19 (11)
|4 (2)
|Chest pain
|11 (6)
|1 (<1)
|Infusion site pain
|11 (6)
|10 (6)
|Catheter site pain
|8 (5)
|Infections and infestations
|Herpes zoster
|18 (10)
|5 (3)
|Upper respiratory tract infection
|18 (10)
|Urinary tract infection
|17 (10)
|4 (2)
|15 (9)
|14 (8)
|9 (5)
|Febrile Neutropenia
|11 (6)
|11 (6)
|Oral Candidiasis
|11 (6)
|2 (1)
|11 (6)
|Weight decreased
|31 (18)
|3 (2)
|Metabolism and nutrition disorders
|40 (23)
|3 (2)
|24 (14)
|8 (5)
|Decreased appetite
|22 (13)
|1 (<1)
|15 (9)
|9 (5)
|Musculoskeletal and connective tissue disorders
|Back pain
|25 (14)
|5 (3)
|11 (6)
|Pain in extremity
|8 (5)
|2 (1)
|Bone pain
|8 (5)
|Nervous system disorders
|36 (21)
|25 (14)
|13 (7)
|Psychiatric disorders
|23 (13)
|14 (8)
|1 (<1)
|10 (6)
|Respiratory, thoracic and mediastinal disorders
|38 (22)
|1 (<1)
|28 (16)
|3 (2)
|Pharyngolaryngeal pain
|14 (8)
|1 (<1)
|8 (5)
|Nasal congestion
|8 (5)
|Skin and subcutaneous tissue disorders
|28 (16)
|1 (<1)
|11 (6)
|Dry skin
|9 (5)
|Night sweats
|9 (5)
|8 (5)
|Vascular disorders
|10 (6)
|2 (1)
|*Patients may have reported more than 1 adverse reaction.
NOTE: Patients counted only once in each preferred term category and once in each system organ class category.
Hematologic toxicities, based on laboratory values and CTC grade, in NHL patients treated in both single arm studies combined are described in Table 4. Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in >1% of patients at Grade 3 or 4, in NHL patients treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%).
In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA. The most common serious adverse reactions occurring in ≥5% of patients were febrile neutropenia and pneumonia. Other important serious adverse reactions reported in clinical trials and/or post-marketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.
Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions [see Warnings and Precautions(5)]. Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.
The following adverse reactions have been identified during post-approval use of TREANDA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including pruritus, irritation, pain, and swelling.
No formal clinical assessments of pharmacokinetic drug-drug interactions between TREANDA and other drugs have been conducted.
Bendamustine's active metabolites, gamma-hydroxy bendamustine (M3) and N-desmethyl-bendamustine (M4), are formed via cytochrome P450 CYP1A2. Inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) have potential to increase plasma concentrations of bendamustine and decrease plasma concentrations of active metabolites. Inducers of CYP1A2 (e.g., omeprazole, smoking) have potential to decrease plasma concentrations of bendamustine and increase plasma concentrations of its active metabolites. Caution should be used, or alternative treatments considered if concomitant treatment with CYP1A2 inhibitors or inducers is needed.
The role of active transport systems in bendamustine distribution has not been fully evaluated. In vitro data suggest that P-glycoprotein, breast cancer resistance protein (BCRP), and/or other efflux transporters may have a role in bendamustine transport.
Based on in vitro data, bendamustine is not likely to inhibit metabolism via human CYP isoenzymes CYP1A2, 2C9/10, 2D6, 2E1, or 3A4/5, or to induce metabolism of substrates of cytochrome P450 enzymes.
Pregnancy Category D [See Warnings and Precautions(5.7)]
TREANDA can cause fetal harm when administered to a pregnant woman. Single intraperitoneal doses of bendamustine from 210 mg/m2 (70 mg/kg) in mice administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal dosing in mice on gestation days 7-11 resulted in an increase in resorptions from 75 mg/m2 (25 mg/kg) and an increase in abnormalities from 112.5 mg/m2 (37.5 mg/kg) similar to those seen after a single intraperitoneal administration. Single intraperitoneal doses of bendamustine from 120 mg/m2 (20 mg/kg) in rats administered on gestation days 4, 7, 9, 11, or 13 caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in external [effect on tail, head, and herniation of external organs (exomphalos)] and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants and tumorigenicity shown for bendamustine in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of TREANDA in pediatric patients have not been established.
In CLL and NHL studies, there were no clinically significant differences in the adverse reaction profile between geriatric (≥ 65 years of age) and younger patients.
Chronic Lymphocytic Leukemia
In the randomized CLL clinical study, 153 patients received TREANDA. The overall response rate for patients younger than 65 years of age was 70% (n=82) for TREANDA and 30% (n = 69) for chlorambucil. The overall response rate for patients 65 years or older was 47% (n=71) for TREANDA and 22% (n = 79) for chlorambucil. In patients younger than 65 years of age, the median progression-free survival was 19 months in the TREANDA group and 8 months in the chlorambucil group. In patients 65 years or older, the median progression-free survival was 12 months in the TREANDA group and 8 months in the chlorambucil group.
Non-Hodgkin's Lymphoma
Efficacy (Overall Response Rate and Duration of Response) was similar in patients < 65 years of age and patients ≥ 65 years. Irrespective of age, all of the 176 patients experienced at least one adverse reaction.
No formal studies assessing the impact of renal impairment on the pharmacokinetics of bendamustine have been conducted. TREANDA should be used with caution in patients with mild or moderate renal impairment. TREANDA should not be used in patients with CrCL < 40 mL/min. [See Clinical Pharmacology(12.3)]
No formal studies assessing the impact of hepatic impairment on the pharmacokinetics of bendamustine have been conducted. TREANDA should be used with caution in patients with mild hepatic impairment. TREANDA should not be used in patients with moderate (AST or ALT 2.5-10 X ULN and total bilirubin 1.5-3 X ULN) or severe (total bilirubin > 3 X ULN) hepatic impairment. [See Clinical Pharmacology(12.3)]
No clinically significant differences between genders were seen in the overall incidences of adverse reactions in either CLL or NHL studies.
Chronic Lymphocytic Leukemia
In the randomized CLL clinical study, the overall response rate (ORR) for men (n=97) and women (n=56) in the TREANDA group was 60% and 57%, respectively. The ORR for men (n=90) and women (n=58) in the chlorambucil group was 24% and 28%, respectively. In this study, the median progression-free survival for men was 19 months in the TREANDA treatment group and 6 months in the chlorambucil treatment group. For women, the median progression-free survival was 13 months in the TREANDA treatment group and 8 months in the chlorambucil treatment group.
Non-Hodgkin's Lymphoma
The pharmacokinetics of bendamustine were similar in male and female patients with indolent NHL. No clinically-relevant differences between genders were seen in efficacy (ORR and DR).
The intravenous LD50 of bendamustine HCl is 240 mg/m2 in the mouse and rat. Toxicities included sedation, tremor, ataxia, convulsions and respiratory distress.
Across all clinical experience, the reported maximum single dose received was 280 mg/m2. Three of four patients treated at this dose showed ECG changes considered dose-limiting at 7 and 21 days post-dosing. These changes included QT prolongation (one patient), sinus tachycardia (one patient), ST and T wave deviations (two patients) and left anterior fascicular block (one patient). Cardiac enzymes and ejection fractions remained normal in all patients.
No specific antidote for TREANDA overdose is known. Management of overdosage should include general supportive measures, including monitoring of hematologic parameters and ECGs.
TREANDA contains bendamustine hydrochloride, an alkylating drug, as the active ingredient. The chemical name of bendamustine hydrochloride is 1H-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl‑, monohydrochloride. Its empirical molecular formula is C16H21Cl2N3O2 ∙ HCl, and the molecular weight is 394.7. Bendamustine hydrochloride contains a mechlorethamine group and a benzimidazole heterocyclic ring with a butyric acid substituent, and has the following structural formula:
TREANDA (bendamustine hydrochloride) for Injection is intended for intravenous infusion only after reconstitution with 20 mL of Sterile Water for Injection, USP, and after further dilution with either 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP. It is supplied as a sterile non-pyrogenic white to off-white lyophilized powder in a single-use vial. Each vial contains 100 mg of bendamustine hydrochloride and 170 mg of mannitol, USP. The pH of the reconstituted solution is 2.5 - 3.5.
Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.
Following a single IV dose of bendamustine hydrochloride Cmax typically occurred at the end of infusion. The dose proportionality of bendamustine has not been studied.
In vitro, the binding of bendamustine to human serum plasma proteins ranged from 94-96% and was concentration independent from 1-50 μg/mL. Data suggest that bendamustine is not likely to displace or to be displaced by highly protein-bound drugs. The blood to plasma concentration ratios in human blood ranged from 0.84 to 0.86 over a concentration range of 10 to 100 μg/mL indicating that bendamustine distributes freely in human red blood cells. In humans, the mean steady state volume of distribution (Vss) was approximately 25 L.
In vitro data indicate that bendamustine is primarily metabolized via hydrolysis to metabolites with low cytotoxic activity. In vitro, studies indicate that two active minor metabolites, M3 and M4, are primarily formed via CYP1A2. However, concentrations of these metabolites in plasma are 1/10 and 1/100 that of the parent compound, respectively, suggesting that the cytotoxic activity is primarily due to bendamustine.
In vitro studies using human liver microsomes indicate that bendamustine does not inhibit CYP1A2, 2C9/10, 2D6, 2E1, or 3A4/5. Bendamustine did not induce metabolism of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 enzymes in primary cultures of human hepatocytes.
No mass balance study has been undertaken in humans. Preclinical radiolabeled bendamustine studies showed that approximately 90% of drug administered was recovered in excreta primarily in the feces.
Bendamustine clearance in humans is approximately 700 mL/minute. After a single dose of 120 mg/m2 bendamustine IV over 1-hour the intermediate t½ of the parent compound is approximately 40 minutes. The mean apparent terminal elimination t½ of M3 and M4 are approximately 3 hours and 30 minutes respectively. Little or no accumulation in plasma is expected for bendamustine administered on Days 1 and 2 of a 28-day cycle.
In a population pharmacokinetic analysis of bendamustine in patients receiving 120 mg/m2 there was no meaningful effect of renal impairment (CrCL 40 - 80 mL/min, N=31) on the pharmacokinetics of bendamustine. Bendamustine has not been studied in patients with CrCL < 40 mL/min.
These results are however limited, and therefore bendamustine should be used with caution in patients with mild or moderate renal impairment. Bendamustine should not be used in patients with CrCL < 40 mL/min. [See Use in Specific Populations(8.6)]
In a population pharmacokinetic analysis of bendamustine in patients receiving 120 mg/m2 there was no meaningful effect of mild (total bilirubin ≤ ULN, AST ≥ ULN to 2.5 x ULN, and/or ALP ≥ ULN to 5.0 x ULN, N=26) hepatic impairment on the pharmacokinetics of bendamustine. Bendamustine has not been studied in patients with moderate or severe hepatic impairment.
These results are however limited, and therefore bendamustine should be used with caution in patients with mild hepatic impairment. Bendamustine should not be used in patients with moderate (AST or ALT 2.5 - 10 x ULN and total bilirubin 1.5 - 3 x ULN) or severe (total bilirubin > 3 x ULN) hepatic impairment. [See Use in Specific Populations(8.7)]
Bendamustine exposure (as measured by AUC and Cmax) has been studied in patients ages 31 through 84 years. The pharmacokinetics of bendamustine (AUC and Cmax) were not significantly different between patients less than or greater than/equal to 65 years of age. [See Use in Specific Populations(8.4, 8.5)]
The pharmacokinetics of bendamustine were similar in male and female patients. [See Use in Specific Populations(8.8)]
The effect of race on the safety, and/or efficacy of TREANDA has not been established. Based on a cross-study comparison, Japanese subjects (n = 6) had on average exposures that were 40% higher than non-Japanese subjects receiving the same dose. The significance of this difference on the safety and efficacy of TREANDA in Japanese subjects has not been established.
Based on the pharmacokinetics/pharmacodynamics analyses of data from NHL patients, a correlation was observed between nausea and bendamustine Cmax.
Bendamustine was carcinogenic in mice. After intraperitoneal injections at 37.5 mg/m2/day (12.5 mg/kg/day, the lowest dose tested) and 75 mg/m2/day (25 mg/kg/day) for four days, peritoneal sarcomas in female AB/jena mice were produced. Oral administration at 187.5 mg/m2/day (62.5 mg/kg/day, the only dose tested) for four days induced mammary carcinomas and pulmonary adenomas.
Bendamustine is a mutagen and clastogen. In a reverse bacterial mutation assay (Ames assay), bendamustine was shown to increase revertant frequency in the absence and presence of metabolic activation. Bendamustine was clastogenic in human lymphocytes in vitro, and in rat bone marrow cells in vivo (increase in micronucleated polychromatic erythrocytes) from 37.5 mg/m2, the lowest dose tested.
Impaired spermatogenesis, azoospermia, and total germinal aplasia have been reported in male patients treated with alkylating agents, especially in combination with other drugs. In some instances spermatogenesis may return in patients in remission, but this may occur only several years after intensive chemotherapy has been discontinued. Patients should be warned of the potential risk to their reproductive capacities.
The safety and efficacy of TREANDA were evaluated in an open-label, randomized, controlled multicenter trial comparing TREANDA to chlorambucil. The trial was conducted in 301 previously-untreated patients with Binet Stage B or C (Rai Stages I - IV) CLL requiring treatment. Need-to-treat criteria included hematopoietic insufficiency, B-symptoms, rapidly progressive disease or risk of complications from bulky lymphadenopathy. Patients with autoimmune hemolytic anemia or autoimmune thrombocytopenia, Richter's syndrome, or transformation to prolymphocytic leukemia were excluded from the study.
The patient populations in the TREANDA and chlorambucil treatment groups were balanced with regard to the following baseline characteristics: age (median 63 vs. 66 years), gender (63% vs. 61% male), Binet stage (71% vs. 69% Binet B), lymphadenopathy (79% vs. 82%), enlarged spleen (76% vs. 80%), enlarged liver (48% vs. 46%), hypercellular bone marrow (79% vs. 73%), "B" symptoms (51% vs. 53%), lymphocyte count (mean 65.7x109/L vs. 65.1x109/L), and serum lactate dehydrogenase concentration (mean 370.2 vs. 388.4 U/L). Ninety percent of patients in both treatment groups had immuno-phenotypic confirmation of CLL (CD5, CD23 and either CD19 or CD20 or both).
Patients were randomly assigned to receive either TREANDA at 100 mg/m2, administered intravenously over a period of 30 minutes on Days 1 and 2 or chlorambucil at 0.8 mg/kg (Broca's normal weight) administered orally on Days 1 and 15 of each 28-day cycle. Efficacy endpoints of objective response rate and progression-free survival were calculated using a pre-specified algorithm based on NCI working group criteria for CLL1.
The results of this open-label randomized study demonstrated a higher rate of overall response and a longer progression-free survival for TREANDA compared to chlorambucil (see Table 5). Survival data are not mature.
|Response Rate n(%)
|Overall response rate
|90 (59)
|38 (26)
|(51.0, 66.6)
|(18.6, 32.7)
|Complete response (CR)*
|13 (8)
|1 (<1)
|Nodular partial response (nPR)**
|4 (3)
|Partial response (PR) †
|73 (48)
|37 (25)
|Progression-Free Survival††
|Median, months (95% CI)
|18 (11.7, 23.5)
|6 (5.6, 8.6)
Hazard ratio (95% CI)
0.27 (0.17, 0.43)
CI = confidence interval
* CR was defined as peripheral lymphocyte count ≤ 4.0 x 109/L, neutrophils ≥ 1.5 x 109/L, platelets >100 x 109/L, hemoglobin > 110g/L, without transfusions, absence of palpable hepatosplenomegaly, lymph nodes ≤ 1.5 cm, < 30% lymphocytes without nodularity in at least a normocellular bone marrow and absence of "B" symptoms. The clinical and laboratory criteria were required to be maintained for a period of at least 56 days.
** nPR was defined as described for CR with the exception that the bone marrow biopsy shows persistent nodules.
† PR was defined as ≥ 50% decrease in peripheral lymphocyte count from the pretreatment baseline value, and either ≥50% reduction in lymphadenopathy, or ≥50% reduction in the size of spleen or liver, as well as one of the following hematologic improvements: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets >100 x 109/L or 50% improvement over baseline, hemoglobin >110g/L or 50% improvement over baseline without transfusions, for a period of at least 56 days.
†† PFS was defined as time from randomization to progression or death from any cause.
Kaplan-Meier estimates of progression-free survival comparing TREANDA with chlorambucil are shown in Figure 1.
The efficacy of TREANDA was evaluated in a single arm study of 100 patients with indolent B-cell NHL that had progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Patients were included if they relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab. All patients received TREANDA intravenously at a dose of 120 mg/m2, on Days 1 and 2 of a 21-day treatment cycle. Patients were treated for up to 8 cycles.
The median age was 60 years, 65% were male, and 95% had a baseline WHO performance status of 0 or 1. Major tumor subtypes were follicular lymphoma (62%), diffuse small lymphocytic lymphoma (21%), and marginal zone lymphoma (16%). Ninety-nine percent of patients had received previous chemotherapy, 91% of patients had received previous alkylator therapy, and 97% of patients had relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab.
Efficacy was based on the assessments by a blinded independent review committee (IRC) and included overall response rate (complete response + complete response unconfirmed + partial response) and duration of response (DR) as summarized in Table 6.
|Response Rate (%)
|Overall response rate (CR+CRu+PR)
|(64.3, 82.3)
|Complete response (CR)
|Complete response unconfirmed (CRu)
|Partial response (PR)
|Duration of Response (DR)
|Median, months (95% CI)
|9.2 months
(7.1, 10.8)
CI = confidence interval
*IRC assessment was based on modified International Working Group response criteria (IWG-RC) 2. Modifications to IWG-RC specified that a persistently positive bone marrow in patients who met all other criteria for CR would be scored as PR. Bone marrow sample lengths were not required to be ≥20 mm.
As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of solutions prepared from TREANDA. The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage. If a solution of TREANDA contacts the skin, wash the skin immediately and thoroughly with soap and water. If TREANDA contacts the mucous membranes, flush thoroughly with water.
Procedures for the proper handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published3-6. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
TREANDA (bendamustine hydrochloride) for Injection is supplied in individual cartons of 20 mL amber single-use vials containing 100 mg of bendamustine hydrochloride as a white to off-white lyophilized powder.
NDC 63459-391-20 TREANDA (bendamustine hydrochloride) for Injection, 100 mg/vial
TREANDA may be stored up to 25°C (77°F) with excursions permitted up to 30°C (86°F) (see USP Controlled Room Temperature). Retain in original package until time of use to protect from light.
Manufactured by:
Pharmachemie B.V.
The Netherlands
Manufactured for:
Cephalon, Inc.
Frazer, PA 19355
TREANDA is a registered trademark of Cephalon, Inc.
© 2008 Cephalon, Inc.
All rights reserved.
Label Code: PI-40014-01
bendamustine hydrochloride injection, powder, lyophilized, for solution


text:
This a-frame tent is so adorable! The tutorial from Cakies for a DIY a-frame tent makes the best play place for little kids. They can read, nap, and play pretend in these awesome little tents. Follow the instructions and make one for your kiddos!
Here are more DIY projects for kids to play with:


text:
Happy Friday! Today we launched in collaboration with Disney a new digital version of the Disney:Legacy Tron Book, built using HTML5. While the site works in any browser, you will get better performance and experience using Internet Explorer 9. This is just one example of how HTML5 coupled with IE Hardware Acceleration can make the web more beautiful today!
You can learn more about the site in the behind the scenes article or Channel9 video interview.


text:
The Groupon Cyber Monday Sale has been extended through today, Tuesday, 12/1!
Score some great deals at up to 80% off for restaurants, manicures, photo books, canvas prints, holiday cards, clothing, paintball adventures, jewelry, concert tickets, candles and much more. These make fabulous gifts!
Click below to see the extended Cyber Monday deals!:
This post may contain affiliate links and I appreciate your using them!


text:
Intel SSD 750 PCIe SSD Review: NVMe for the Client
Ever since our SSD DC P3700 review, there's been massive interest from enthusiasts and professionals for a more client-oriented product based on the same platform. With eMLC, ten drive...134 by Kristian Vättö on 4/2/2015
The State of Wireless Charging Standards in Mobile
A look through the various competing wireless charging standards, their advantages, disadvantages, and where the future leads to.89 by Andrei Frumusanu on 4/2/2015
LG 34UM67: UltraWide FreeSync Review
AMD officially launched FreeSync earlier this month, and the technology is interesting not just in how it works but also in how it differs from NVIDIA's G-SYNC. Our first...96 by Jarred Walton on 3/31/2015
The Samsung SSD 850 EVO mSATA/M.2 Review
Four months ago Samsung introduced the world to TLC V-NAND in the form of SSD 850 EVO. It did well in our tests and showed that 3D NAND technology...58 by Kristian Vättö on 3/31/2015
The Phanteks Enthoo Pro Case Review
The Enthoo Pro is most popular tower case of Phanteks, which the company claims to be "beautifully crafted, amazingly flexible, budget friendly and with maximized cooling potential". One might...49 by E. Fylladitakis on 3/30/2015
Exploring DirectX 12: 3DMark API Overhead Feature Test
This week the benchmarking gurus over at Futuremark are releasing their own first run at a DirectX 12 test with their latest update for the 3DMark benchmark. Futuremark has...113 by Ryan Smith & Ian Cutress on 3/27/2015
Samsung Galaxy S 6 and S 6 Edge: Preview
Yesterday we received our Galaxy S6 and S6 edge review units. We're still working on the final review but I wanted to share some early results from both devices...200 by Joshua Ho on 3/26/2015
The ASUS Zenbook UX305 Review
It was way back in 2011 that ASUS launched the Zenbook series. The original UX21E and UX31E were the first of the thin and light Ultrabooks from ASUS to...164 by Brett Howse on 3/25/2015
The OCZ Vector 180 (240GB, 480GB & 960GB) SSD Review
OCZ has been teasing the Vector 180 for quite some time now. The first hint of the drive was unveiled over nine months ago at Computex 2014 where OCZ...89 by Kristian Vättö on 3/24/2015
The Rosewill Photon 1050W Review
It has been nearly three years since our last review of a Rosewill PSU and the company is now back with an entirely new series, the Photon. With the...42 by E. Fylladitakis on 3/24/2015
The HTC One M9 Review: Part 1
For the most part, HTC's story in the recent past has been well-understood. Starting with the G1, HTC was the first to adopt Android, with massive success as others...132 by Joshua Ho on 3/22/2015
Clevo P750ZM: GTX 980M Overclocking Investigated
We posted our full review of the Eurocom P5 Pro (Clevo P750ZM) last week and mentioned that we were investigating overclocking potential. Armed with an updated VBIOS and running...34 by Jarred Walton on 3/20/2015
The AMD FreeSync Review
After a long wait, AMD's FreeSync has finally arrived. Promising adaptive refresh rates using open standards and with no royalty fees, there are only two remaining questions: does is...350 by Jarred Walton on 3/19/2015
The NVIDIA GeForce GTX Titan X Review
Never one to shy away from high-end video cards, in 2013 NVIDIA took the next step towards establishing a definitive brand for high-end cards with the launch of the...276 by Ryan Smith on 3/17/2015
NVIDIA GTC 2015 Keynote Live Blog47 by Ryan Smith on 3/17/2015
The Chromebook Pixel (2015) Review
Google's Chrome OS has always been similar to Microsoft Windows in how one company provides the operating system for many different manufacturers to use on their own devices. But...123 by Brandon Chester on 3/16/2015
Lenovo Yoga 3 Pro Review: Refreshed With Faster Core M
It would be fair to say that Lenovo was a pioneer in the convertible Ultrabook lineup with the original Yoga. Last year, they updated the Yoga lineup with the...113 by Brett Howse on 3/13/2015
The Dell Venue 8 7000 Series Review
Five years ago, the first of what we would call modern tablet computers were released to the world. What is now an entire product category was originally seen with...89 by Brandon Chester on 3/12/2015
The ASRock X99 Extreme11 Review: Eighteen SATA Ports with Haswell-E
If there is one thing I like about ASRock, it is their ability to do something different in an increasingly difficult market to differentiate. One of these elements is...58 by Ian Cutress on 3/11/2015
Eurocom P5 Pro / Clevo P750ZM Review: True DTR
Some people look at notebooks as a way to cut the cord and go mobile for long periods of time, but others view the portability as a mere convenience...74 by Jarred Walton on 3/10/2015


text:
Harry Potter Studio Tour
posted in: Top Destinations, United Kingdom | 14
We spent eighteen months outside the UK and Emily's favourite bit was coming home and going on the Harry Potter Studio Tour. Here she explains why. We didn't want to come home from Australia, that's how we ended up buying … Continued


text:
Boys hockey: Kobienia's hat trick powers Cardinals
WILLMAR — Sophomore wing Isaac Kobienia scored the hat trick and had helpers on four other goals while senior goalie Levi Goosman returned to the cage after a month-long absence spurring Willmar to an 8-2 win over the Golden Bears of Eveleth-Gilbert on Friday evening.
Goosman, who had 23 stops, last played Dec. 14, a 3-1 win at Marshall. The next week he broke the thumb on his blocker hand while refereeing adult hockey.
Willmar also plugged in its power play generating three goals through two periods for a 4-1 lead on the Golden Bears (9-4-1).
Kobienia's seven points is astonishing for the 150-pound sophomore playing on the first line with Hunter Mottinger and EvanVanDenEinde. But he has been on fire this month. In a recent JV game, he scored four straight goals in the third period alone.
Mottinger supplied four points and two goals. Riley Grabow, Cole Hagen and Buzzy Tollefson also scored goals.
Sam Roberts and Mitch Huffman scored for E-G, who play in Hutchinson today.
Also today, at 3 p.m. at the Cardinal Arena, Willmar plays Virginia/Mt. Iron-Buhl.
"Goosman had some big save early and when we got that power play goal early that all gave us confidence," said coach Dan Tollefson.
Will. 8, Eveleth-Gilbert 2
Eveleth-Gilbert (9-4-1) 1 1 2 — 2
Willmar (7-7) 3 1 4 — 8
FIRST PERIOD – Wil: Isaac Kobienia (Tyler Pendill) 3:42, pp … Wil: Riley Grabow (Kobienia, Evan VanDenEinde) 5:07 … . Wil: Hunter Mottinger (Kobienia, Pendill), pp …. EG: Sam Roberts (Zach Skelton) 14:53
SECOND PERIOD – Wil: Kobienia (Buzzy Tollefson, Pendill) 6:50, pp
THIRD PERIOD – fW: Kobienia (Mottinger,VanDenEinde) 2:43 … EG: Mitch Huffman (nick Moe) 3:05 … W: Cole Hagen (Nate Ackerman, Joey Lee) 6:13 … W: Mottinger (Ackerman, Kobienia) 9:24 … W: Tollefson (Kobienia), Mottinger) 10:18
GOALIE SAVES – Eveleth-Gilbert: Chad Hietela 12-9-6, Grant Kokal *-*-2-2 … Willmar: Levi Goosman 7-11-5-23


text:
Pork producer margins retreated last week, but remain positive as negotiated cash hog prices lost $2.60 per hundredweight.
Producer margins last week averaged $4.57 per head according to the Sterling Pork Profit Tracker. Last week's margins were below the $13.51 average a week earlier and $5.96 average a month ago. Last week's margins did remain positive and are $19.66 above the negative $15.09 recorded a year ago.
Lower feed costs moved the calculated breakeven price $5.13 per head lower than a week earlier.
Pork packer margins remain negative and lost an additional $1.40 per head last week, moving to negative $4.45 per head.
Cash trade plays a major role in feeder and packer profit margins this week as a $2 increase above the previous week pushes profit margins in opposite directions.
Feeder profit margins averaged $76.48 last week, increasing $33.60 per head compared to the previous week according to the Sterling Beef Profit Tracker. Feeder margins are drastically higher than a month earlier when the average was negative $57.96 per head and are even better than the negative $83.47 average this time last year.
Cash prices improving by over two dollars, selling at $126 per hundredweight and slightly lower feed costs, down 60 cents per head contributed to higher feeder margins.
Packer margins fell lower, down $11.72 to average negative $35.35 according to estimates by Sterling Marketing, Inc., Vale, Ore. Packer margins were $18.27 per head a month earlier and negative $54.58 a year ago. Packer losses were eased by beef cutout prices inching 79 cents higher.
The Sterling Pork Profit Tracker for the week ending September 27:
- Average farrow-to-finish margins: $4.57 per head.
- Average pork packer margins: -$4.45 per head.
The Sterling Beef Profit Tracker for the week ending September 28:
- Average feedyard margins: $76.48 per head.
- Average packer margins: -$35.35 per head.
The Sterling Beef and Pork Profit Trackers are produced by Sterling Marketing Inc. and John Nalivka, president, Vale, Ore., and are published weekly by Drovers/CattleNetwork, and PorkNetwork.


text:
TrustFire Protected 18650 Lithium Battery (2500mAh 2-Pack Blue)
If you think the price is too high, please click to apply for lower price
All packages from DX.com are sent without DX logo or any information indicating DX.com. Due to package variations from suppliers, the product packaging customers receive may be different from the images displayed.
To enable volume discounts on this site, use coupon code: BULKRATE during checkout. You will see a discount applied at the bottom of the shopping cart. Competitive pricing is available. Contact us for details.
|3+ units
|5+ units
|10+ units
|US$6.47 shipped
|US$6.45 shipped
|US$6.43 shipped
What is Bulk Rate? BulkRate is a semi-wholesale system with items priced separately from retail. When you use bulk rates, a flat $1.70 registered air mail fee will automatically be added to your cart to ensure delivery of package. While BulkRate's intention is to offer cheaper prices when you buy in bulk, because it is priced separately it on occassions show a higher than retail price. That's why we ask you to enter BULKRATE as a coupon code to manually activate the rates. You can always opt not to use the bulk rates. If you are looking for wholesale prices please feel free to contact us.
Share your reviews, photos and videos here!Review Program
It last longer than regular batteries, very good for the money! I would buy it again! The product description that DX made on the products really helps a lot! Especially on the flashlights!
Nu am ce comenta prea mult. Se incarca ... tin destul de bine ... isi fac treaba. Cat timp? Voi vedea.
Bateria muito boa, com carga de longa duração e excelente potência de descarga. Infelizmente, esse tipo de produto não pode mais ser enviado ao Brasil devido a restrições relativas a segurança de vôo.
Это повторный заказ аккумуляторов, первые надёжно служат шестой год, и я ими очень довольна! Используются в велосипедной фаре, заряжаются за пару часов, за время использования потери ёмкости не заметила. Поэтому смело в... Read more
Pros: good capacity, fair price, nice and practical case, works Cons: you need a special battery charger
It last longer than regular batteries, very good for the money! I would buy it again! The product description that DX made on the really... Read more
Nu am ce comenta prea mult. Se incarca ... tin destul de bine ... isi fac treaba. Cat timp? Voi vedea.
protected cells, comes in pairs in a plastic reusable container price, seemed more than fair UNTIL i checked capacity levels in the 6 i 6... Read more
Please note that DealExtreme Forums are not a sales or product support board. For support questions, please contact us via support ticket at http://cs.dx.com/ for a guaranteed response. We make every effort to make the quickest replies.


text: >>>>> "Tim" == Tim Churches <tchur at optusnet.com.au> writes: Tim> Yes, I agree entirely. Travis, you are at perfect liberty to Tim> create commercial documentation for SciPy Core, but please Tim> don't object if others try to organise to create free open Tim> source documentation as well. Object? I'll bet dollars to doughnuts that Travis would be delighted to see this, just as he would have been at any time over the last several years. And be careful: Perry still owes me a doughnut. JDH


text:
Cart is empty
The Chelsea Sconce
Product Details
Add urban styling to your front entry, hallway, or guest bath with the Chelsea Sconce! Its stylish teardrop bulb hangs on an exposed silk cord and is mounted on a satin black industrial wall fixture. This chic modern sconce would also be suitable for commercial applications such as restaurants, galleries, and retail stores. Add the finishing touch with a nostalgic Edison Style Light Bulb!
- Shade Size:.4.5"W x 14"H
- Glass Size: 6 ¼"H x 4 ½" Dia
- Mounting: Wall Mounted
- Wall Plate: 4 ½"W x 6"H
- Finish: Satin Black
- Max Wattage Per Socket: 75W Standard Incandescent (Bulb Not Included)
- Number of Sockets: 1 (Med Base)
- UL Listed for Dry Locations
- Imported Fixture
Customer Reviews
09/11/2013, 13:30


text:
The best advice my mother ever gave me. What's some good advice that your mom or dad ever gave you?
"If they already think you're a whore, then go ahead and act like one."
|by Anonymous
|reply 29
She told me to keep both feet on the floor during a date.
|by Anonymous
|reply 1
That's some awful and sad advice, op. Still, tell your mom to email me. I'd love to have drinks with her.
|by Anonymous
|reply 2
"Men only want one thing", knowing that saved me from boring dinners and movies. Just get straight to the good stuff.
|by Anonymous
|reply 3
My father once said "There are the girls you screw and the girls you marry. Learn the difference." Strangely I turned into one of the girls you screw later on.
|by Anonymous
|reply 4
Never wear cheap cologne.
Check out a man's shoes and his nails. If they are unkempt, it will tell you a lot.
|by Anonymous
|reply 5
Push down, like you're taking a dump.
God, how I miss Dad.
|by Anonymous
|reply 6
Upon learning that I had sex with our neighbor's husband my mother said...
"You have your daddy's lack of morals and your mother's taste in men. You'll never settle down."
That old broad was right, God rest her soul.
|by Anonymous
|reply 7
My mother told me to stay away from families like your family, OP.
|by Anonymous
|reply 8
To lift my feet off the car floor when driving over railroad tracks - supposedly it brought good luck against getting preggers.
|by Anonymous
|reply 9
Career advice from Mom: Don't rob gas stations.
|by Anonymous
|reply 10
OP, that's the advice I gave myself in high school. I hadn't a reputation for being a whore, but rather... gay.
|by Anonymous
|reply 11
"If you just follow the crowd, you'll only get as far as they do."
|by Anonymous
|reply 12
"Find a partner. Don't go through life alone."
|by Anonymous
|reply 13
Sadly, none.
|by Anonymous
|reply 14
"It's as easy to marry a rich man as it is to marry a poor man."
|by Anonymous
|reply 15
"You can only rely on yourself because people are assholes".
|by Anonymous
|reply 16
God doesn't give you greater challenges than you can handle.
|by Anonymous
|reply 17
[Crying during a conversation a week or so after I came out at 19 in 2000)
"If you're as good at fuckin' men as all the [her maiden name] are, you're gonna end up with AIDS."
I stayed a virgin until I was 28... She was wrong about the AIDS, but oh so right about inherited talent.
|by Anonymous
|reply 18
"You can't get something for nothing."
Duh, of course, as you get older and wise up, but good advice for naive younger people who think they're getting an amazing, cheap bargain.
|by Anonymous
|reply 19
If people accuse you of something just go ahead and do it. Always have a spare lover to run to in case your main squeeze dumps you. Freedom of speech is worthless If you dont use it.
|by Anonymous
|reply 20
R20, that is astoundingly shitty advice.
|by Anonymous
|reply 21
Mom told me "If you know you're going to take a throbbing stiff cock up your ass, then an anal douche beforehand is just good manners."
|by Anonymous
|reply 22
"There are those that matter, those that don't, and those that never did. When you got that sorted out, you got it all figured out."
"Life is like a box of chocolates. There's only a couple in there that's really worth eating."
|by Anonymous
|reply 23
"There's no such thing as a free lunch"
|by Anonymous
|reply 24
Don't loan money and expect to be paid back.
|by Anonymous
|reply 25
If they'll cheat to be with you, don't be surprised when they cheat on you.
|by Anonymous
|reply 26
Always leave the house with clean underwear.
|by Anonymous
|reply 27
"the first to file a lawsuit or call the cops always wins"
To my cost I did not believe her.
|by Anonymous
|reply 28
Similar to R19:
You get what you pay for.
|by Anonymous
|reply 29


text:
Cat Waves Down Passerby To Be Rescued
And then the cat attacked the Avon lady. Oops, different cat.
A cat stuck in a wall at a house under construction initiated his rescue when he caught the attention of a prospective buyer by meowing and waving his paw out a small hole.
The cat had gotten stuck behind the wall but found a gap between a gas pipe and the wall board where he could stick out his paw. He was spotted Saturday by someone touring the house.
Collierville Animal Services supervisor Nina Wingfield said she heard a "hoarse meow" after she arrived at the house.
"When he knew we were there, it was a very hoarse, frantic meow," she said. Wingfield freed the feline by cutting away the wall board with a knife.
"He had his paw out touching — not clawing — the whole time, like he was saying 'Come on! Come on,'" Wingfield said.
She thinks the cat, who had been stuck without food long enough for his ribs to be showing, is a lost pet. The owners have until Friday to come forward and claim him before he will be offered for adoption to someone else.
In the meantime, the animal shelter is calling him by a new name: Wally.


text:
Details & Care
Precise darts at the waist nip in the tailored shape of a lovely techno-knit dress styled with a smooth yoke of tonal silk jersey.
- Approx. length from shoulder to hem: 40 1/2".
- Measurements taken from size 8 and may vary slightly by size.
- Back zip closure.
- Short sleeves.
- Back vent.
- Cotton lining.
- Cotton; yoke is silk; dry clean.
- Made in Italy.
- Collectors.
- Item #619234


text:
It seems you're using a browser that is a little past its time and our website might not be able to perform as it should.
If you'd like to have the best experience on WellingtonNZ.com, you can easily update your browser to get the most out of our website and many more for that matter.dismiss this message
Is your business embracing winter with special celebrations? Be sure to tell us all about it!
We want to know what your business is up to this winter so we can shout about it, as part of our new winter marketing campaign, to all those potential visitors out there enticing them with lots of reasons why they need to head to Wellington this winter.
We're talking special menus, new brews, winter-inspired cocktail lists, new season items in-store... the list goes on!
And a few questions about what you personally love about winter in Wellington as a local business owner.
ID: {{ userItinerary.ID }} | Days: {{ userItinerary.TotalDays }} | Activities: {{ userItinerary.TotalActivities }}


text:
Longer Screen, Smaller Dock Connector Included in Latest Round of iPhone 5 Rumors
Folks have been talking about a "bigger" screen for months, but now are we starting to hear more details about what size display might come equipped on the next-gen iPhone. Rumors attributed to sources who have allegedly tested Apple's next handset (or at least one of the prototypes) indicate that the coming device might retain the 1.94-inch screen width while bumping the height up to 3.95 inches.
As tired as these screen size rumors are getting, this one does gel pretty well with how we might expect Apple to do things… Rather than throwing out the mold and adding inch after inch to keep up with Android's ballooning screen sizes, perhaps Apple while give us a marginal increase. After many years with the same size screen, there's no doubt that a 3.95-inch screen—while not competing with the largest of Android screens—would feel like a major upgrade.
And along with giving us more to look at, the new aspect ration of such a screen would by 16:9. While that might not sit well with developers who have to revamp their app offerings, it would seem beneficial for Apple to get the iPhone and iPad on the same page.
Even though the sources for these rumors have supposedly had their hands on Apple's next iPhone, no more details have emerged due to the devices being hidden inside bulky, locked shells… The units are said to be running a build of iOS 6 that allows room for a fifth row of apps, and there is talk of the dock connector being smaller than what is currently in use.
All things considered, it seems as though these size rumors are starting to fit inside more of an Apple-sized package. But who's to say what we'll actually end up getting come October?


text:
Dear Community Member,
Remember the last time you were truly lost?
We're talking about the kind of helplessness and uncertainty where directions aren't found on a map or recalculated on a GPS.
During those times, what's needed most is a safe, warm place.
The Gay & Lesbian Community Center (GLCC) of Pittsburgh is that place for Pgh's LGBTQ community. For the families and friends of people identifying as gay, lesbian, bisexual, transgender, or queer, we're that safe place for them too.
We're the place where those who have been silenced are finally heard, where connections with others are made, every day, and where acceptance is found in abundance.
Several weeks ago, Sophia* stopped by the GLCC's offices at 210 Grant Street on her lunch hour. A paralegal at a Downtown law firm, she noticed the sign over the door and checked out our website at www.glccpgh.org. Her motivation for taking the brave step of opening our door was her 12 year old child who wasn't "growing out" of his interest in "girl things." As a mom, Sophia was worried and upset. We talked to her for an hour about gender identity and told her about programs and resources that might help ease her concerns.
The GLCC of Pittsburgh is Sophia's community center.
Shortly after relocating to Pittsburgh for his corporate marketing job, Keith* called our phone line (412-422-0114) looking for activities where he could meet others identifying as LGBTQ. He wasn't interested in the bars but preferred socializing with others in a safe, friendly environment. A GLCC volunteer told Keith about several events happening that weekend near his North Hills home.
The GLCC of Pittsburgh is Keith's community center.
The GLCC of Pittsburgh is your community center, too.
Sophia and Keith were just two people who received support from The GLCC of Pittsburgh. There are thousands of others just like them that have come to rely on the GLCC every year for very similar support.
That's why we're asking you to support The GLCC of Pittsburgh today with your one time or monthly tax-deductible financial gift.
Regardless of the amount, your contribution will help provide critically-needed programs for Pittsburgh's LGBTQ community and those who care about them. Programs such as:
∙ HIV testing
∙ Access to basic health care
∙ Social activities
∙ Youth programs
∙ After School offerings
∙ Homeless outreach and Resource Drop In
∙ Innovative partnerships with other LGBTQ organizations throughout the Western Pennsylvania region
While recent events and historic milestones may seem to indicate a lessening need for such services, the opposite is actually true. At The GLCC of Pittsburgh, increased awareness has led to an unprecedented need among the LGBTQ community. That's why your support is more critical now than ever.
As an all-volunteer nonprofit, even more of your donation goes directly to supporting programs. It's what keeps The GLCC of Pittsburgh a safe and warm place, for you, for everyone.
We thank you in advance for your generosity.
-The Gay & Lesbian Community Center of Pittsburgh
*Confidentiality is pretty important to us at The GLCC …which is why Sophia and Keith's names aren't their real ones. (And if you prefer, we'll keep your donation anonymous too. Just let us know.)


text:
This property has been removed by the agent. It may be let or temporarily removed from the market
Property Description
Letting information:
|Added on Rightmove:
|20 February 2012 (2044 days ago)
Full description
A well presented town house with hallway, sitting/dining room benefiting from dividing doors and door to rear garden. Modern kitchen, bathroom with separate shower cubicle to the bath, two double bedrooms and good size single bedroom. Rear garden. One off street parking space (accessed via George Street) to the rear of the house. Unfurnished.
Map & Street View
View in fullscreenView in fullscreen
Street View is unavailable in this location
Disclaimer - Administration fees may apply when renting a property in England, Wales or Northern Ireland. For more details, please contact the agent.
Property reference 832458. The information displayed about this property comprises a property advertisement. Rightmove.co.uk makes no warranty as to the accuracy or completeness of the advertisement or any linked or associated information, and Rightmove has no control over the content. This property advertisement does not constitute property particulars. The information is provided and maintained by Leaders , Cambridge - Lettings.
Please refer to our Renting Guides for further information on how to safely rent a property.
Map data ©OpenStreetMap contributors.


text:
It's September, so that means one thing to Will Darkins - the season is starting. The tough 6-foot-2, 217-pound inside linebacker from Lake Oswego High School had fun this offseason, participating...
Premium Content
Subscribe today to read the full article and get everything Rivals has to offer.
- Member-only message boards
- Exclusive highlights and recruiting interviews
- Exclusive coverage of Rivals Camp Series
- Breaking recruiting news


text:
|Bryan, TX
College Station, TX
Huntsville, TX
Palestine, TX
Brenham, TX
|Conroe, TX
Robinson, TX
Bellmead, TX
Hewitt, TX
The Woodlands, TX
|Waco, TX
Tomball, TX
Woodway, TX
Temple, TX
Corsicana, TX
The center of each city listed is within 77 miles of Normangee, TX.
Scroll down the page to find a list of big cities if you're booking a flight between airports, or a list of smaller surrounding towns if you're doing a road trip.
This is a list of large cities closest to Normangee, TX. A big city usually has a population of at least 200,000 and you can often fly into a major airport. If you need to book a flight, search for the nearest airport to Normangee, TX.
This is a list of smaller local towns that surround Normangee, TX. If you're planning a road trip or exploring the local area, make sure you check out some of these places to get a feel for the surrounding community.
Travelmath helps you find cities close to your location. You can use it to look for nearby towns and suburbs if you live in a metropolis area, or you can search for cities near any airport, zip code, or tourist landmark. You'll get a map of the local cities, including the distance and information on each town. This can help in planning a trip or just learning more about a neighboring city so you can discover new places.


text:
Earlier this month, NBC gave a quick greenlight for Bryan Fuller's upcoming reboot of "The Munsters." And less than two weeks later, a feature film director is already on board.
Deadline is reporting that Bryan Singer is in final negotiations to direct the pilot episode of "The Munsters" and join the project as an executive producer alongside Fuller. The new "Munsters" has been described as "'Modern Family' meets 'True Blood'" and it is rumored to be in line for a potential summer debut.
Singer is best known for directing the feature films "The Usual Suspects," "Valkyrie," "Apt Pupil" and "Superman Returns" as well as the first two "X-Men" movies. "The Munsters" won't be Singer's first entry into television. Singer has previously helmed the pilot episodes of "Football Wives" and "House," where he remains attached as an executive producer. Singer has also produced the TV series "Dirty Sexy Money" and the miniseries "The Triangle" which aired on Syfy. Singer's next feature film is the upcoming, "Jack the Giant Killer."
Although "The Munsters" will be the first teaming of the two Bryans, Fuller previously worked with feature film director Barry Sonnenfeld ("Men in Black") on the pilot for "Pushing Daisies." NBC was also reportedly searching for a top director to attach to "The Munsters," which makes Singer's fast signing less surprising.
If "The Munsters" gets ordered to series, it may air as soon as Summer 2012.
Photo credit: Adriana M. Barraza/WENN.com
Do you think that Bryan Singer can make the updated "Munsters" work onscreen? Sound off in the comment section below!


text:
The pirate site plans to ignore the lawsuits from Elsevier and the American Chemical Society.
Replication Complications
January 18, 2017|
An initiative to replicate key findings in cancer biology yields a preliminary conclusion: it's difficult.
January 18, 2017|
An initiative to replicate key findings in cancer biology yields a preliminary conclusion: it's difficult.
January 17, 2017|
Clostridium botulinum produces a transcription factor that can aggregate and self-propagate a prion-like form, leading to genome-wide changes in gene expression in E. coli, according to a study.
January 13, 2017|
The findings suggest language may have started to evolve millions of years earlier than once thought.
January 11, 2017|
A team of scientists was unable to replicate controversial, high-profile findings published in 2011.
January 3, 2017|
Anole lizards inhabiting the Caribbean islands display some of the key principles of evolution.
January 1, 2017|
The small lizards adapted to unique niches among dozens of isles.
January 1, 2017|
The Asian honeybee should have been crippled by low genetic diversity, but thanks to natural selection it thrived.
January 1, 2017|
The public may still believe that male-specific traits, such as high testosterone levels, lead to many of the gender inequalities that exist in society, but science tells a different story.
December 29, 2016|
Audio recordings of bats hashing out disputes reveals that their calls are laden with information about identity and intent.
December 14, 2016|
Standard taxonomy lumps together bird species that should be separate, a new study suggests, raising the total number of estimated species from 9,000 to 18,000.


text:
Finance crisis good for business: Ryanair boss
Michael O'Leary last night delivered a buoyant economic forecast in the face of the global financial crisis.
He insisted that the credit crunch was "good for business" and said his low fares airline would reap the benefits of the financial gloom.
"We are not just looking at a recession but a depression," the colourful businessman said.
"We are really looking at four or five years of recessionary economics and that's great for Ryanair's business.
"People are down-trading. Everyone will be wanting to trade down now.
"We have a great economic outlook, the great thing about flying is that people will never stop.
"They have got to go to weddings or stag parties, they have to go home for Christmas, they need to fly to work.
"In the past, in recessions, more and more people started to trade down and that's exactly what's going to happen in the next few years.
"If you can't make money in this business you'd be a fool."
Speaking at the London Chamber of Commerce, Mr O'Leary added that he wanted to double his company's traffic and profits by 2012.
The Irishman's defiant predictions contrast with the economic difficulties currently stalking the travel industry.
In July, budget airline Zoom went into administration and grounded all its flights, with XL Leisure following in September, both companies blaming the rising cost of oil for the collapse.
Mr O'Leary said he thought "more would follow" in their wake.
He blamed the industry regulator the Civil Aviation Authority (CAA) for not monitoring the companies' situations more closely and leaving passengers stranded.
"They did nothing," he said. "They should have firmly told them to stop taking bookings. Instead things went tits up and thousands of passengers are left stranded."
Belfast Telegraph